High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Stem Cell Support: a New Regimen for the Treatment of Multiple Myeloma

REFERENCES

• Alexanian, R. and Dimopoulos, M. (1994) "The treatment of multiple myeloma", New England Journal of Medicine, 330, 484 — 489.
   PubMed Web of Science ®Google Scholar
• Attal, M., Harrousseau, J., Stoppa, A., Sotto, J., Fuzibet, J., Rossi, J., et al. (1996) "A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma", New England Journal of Medicine, 335, 91— 97.
   Google Scholar
• Besinger, W.I., Rowley, S.D., Demirer, T., Lilleby, K., Schiffman, K., Clift, R.A., et al. (1996) "High dose therapy followed by autologous hematopoietic stem cell infusion for patients with multiple myeloma", Journal of Clinical Oncology, 14, 1447–1456.
   Google Scholar
• Barlogie, B., Jagannath, S., Naucke, S., Mattox, S., Bracy, D., Crowley, J., et al. (1998) "Long term follow-up after therapy for high risk multiple myeloma", Bone Marrow Transplantation, 21, 1101 —1107.
   PubMed Web of Science ®Google Scholar
• Vesole, D.H., Crowly, J.J. and Catchatrourian, R. (1999) "High-dose melphalan with autotransplantation for refractory multiple myeloma: Results of a Southwest Oncology Group phase II trial", Journal of Clinical Oncology, 17, 2173–2179.
   PubMed Web of Science ®Google Scholar
• Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., et al. (1998) "Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation", British Journal of Haematology, 102, 1115 — 1123.
   Google Scholar
• Bearman, S.I., Appelbaum, F.R., Buckner, C.D., Petersen, F.B., Fisher, L.D., Clift, R.A., et al. (1988) "Regimen-related toxicity in patients undergoing bone marrow transplantation", Journal of Clinical Oncology, 6(10), 1562–1568.
   PubMed Web of Science ®Google Scholar
• McElwain, T.J. and Powels, R.L. (1983) "High-dose intravenous melphalan for plasma cell leukemia and myeloma", Lancet, 2, 822 — 824.
   Google Scholar
• Barlogie, B., Hall, R., Zander, A., Dicke, K.A. and Alexanian, R. (1986) "High-dose melphalan and autologous bone marrow transplantation for resistant multiple myeloma", Blood, 67, 1298 — 1301.
   Google Scholar
• Barlogie, B., Jagannath, S., Desikan, KR., Mattox, S., Vesole, D., Siegel, D., et al. (1999) "Total therapy with tandem transplants for newly diagnosed multiple myeloma", Blood, 93, 55–65.
   Google Scholar
• Lahuerta, J.J., Grande, C., Martinez-Lopez, J., De La Serna, J., Toscano, R., Oritz, M.C., et al. (2003) "Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Espafiol de Sindromes Linfoproliferativos/Trasplante Auffilogo de Medula Osea phase II trial", British Journal of Haematology, 120(2), 296— 303.
   PubMed Web of Science ®Google Scholar
• Segeren, C.M., Senneveld, P., van der Holt, B., Vellenga, E., Croockewit, A.J., Verhoef, G.E., et al. (2003) "Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study", Blood, 101(6), 2144–2151.
   PubMed Web of Science ®Google Scholar
• Lahuerta, ii., Martinez-Lopez, J., Grande, C., Blade, J., de la Serna, J., Alegre, A., et al. (2000) "Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma", British Journal of Haematology, 109, 138–147.
   PubMed Web of Science ®Google Scholar
• Desikan, KR., Tricot, G., Dhodapkar, M., Fassas, A., Siegel, D., Vessole, D.H., et al. (2000) "Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior to historical controls receiving tandem transplants with melphalan alone", Bone Marrow Transplantation, 25(5), 483–487.
   PubMed Web of Science ®Google Scholar
• Donato, M.L., Gershenson, D.M., Wharton, J.T., Ippoliti, C.M., Aleman, AS., Bodurka-Bevers, D., et al. (2001) "High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer", Gynecologic Oncology, 82, 420–426.
   PubMed Web of Science ®Google Scholar
• Kraut, E.H., Crowley, ii., Wade, J.L., Laufman, L.R., Alsina, M., Taylor, S.A., et al. (1998) "Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group Study", Journal of Clinical Oncology, 16, 589–592.
   PubMed Web of Science ®Google Scholar
• Armstrong, D. and O'Reilly, S. (1998) "Clinical Guidelines for managing topotecan-related hematologic toxicity", Oncologist, 3(1), 4–10.
   PubMedGoogle Scholar
• Janss, A.J., Cnaan, A., Zhao, H., Shpilsky, A., Levow, C., Sutton, L., et al. (1998) "Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lives", Anticancer Drugs, 9(7), 641–652.
   PubMed Web of Science ®Google Scholar
• Murren, J.R., Anderson, S., Fedele, J., Pizzorno, G., Belliveau, D., Zelterman, D., et al. (1997) "Dose-escalation and pharmacody-namic study of topotecan in combination with cyclophosphamide in patients with refractory cancer", Journal of Clinical Oncology, 15(1), 148–157.
   PubMed Web of Science ®Google Scholar